A migraine is characterized by repeated attacks of a severe headache, nausea, vomiting, and extreme sensitivity to light and sound. Women are more prone to the disease compared to men owing to the fluctuating levels of hormones in their bodies. Therapeutic agents such as anti-inflammatory painkillers, antimigraine drugs, antisickness medicines, and triptans are used for the treatment of the disease.
Technavio’s analysts forecast the global migraine drugs market to grow at a CAGR of 4.56% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global migraine drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that will be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Migraine Drugs Market 2016-2020
Technavio recognizes the following companies as the key players in the Global Migraine Drugs Market: Allergan, Endo International, GlaxoSmithKline, Impax, and Pfizer.
Other Prominent Vendors in the market are: Abbott, Aegis Therapeutics, Aeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, AstraZeneca, Bayer, CoLucid, Dr. Reddy’s Laboratories, Eisai, Eli Lilly, Ethypharm, IntelGenx, Johnson & Johnson, Klaria, Kowa Pharmaceuticals America, Luitpold Pharmaceuticals, Meda, Merck, OptiNose, Pfizer, Pozen, Raptor, RedHill, SUDA, Teva, TG Therapeutics, NValeant, Winston Pharmaceuticals, and Zogenix.
Commenting on the report, an analyst from Technavio’s team said: “One market trend to watch for is the development and availability of antimigraine devices and headbands. Antimigraine drugs are associated with various side effects and show less tolerance among the patients. Thus, the need for new treatment options has led to the development of various devices in the market. Antimigraine devices and headbands are being increasingly preferred for the prevention of migraines. The FDA has approved Cerena Transcranial Magnetic Stimulator and the Cefaly Transcutaneous Electrical Nerve Stimulation device for migraine treatment. Cefaly is a plastic headband, which can be worn across the forehead.”
According to the report, a key market driver is the unmet needs of migraine sufferers around the world. Prophylactic therapy with improved efficacy and tolerability is one of the most significant unmet needs in individuals suffering from migraine. The US Agency for Healthcare Research and Quality estimated that only about 12% of the adults with migraines take preventive medications. The occurrence of side effects is the major reason that limits the use of migraine drugs. Moreover, there are still high levels of unmet need existing in certain niche populations, especially in patients who do not respond satisfactorily to triptans or patients for whom triptans are contraindicated.
Further, the report states that a challenge that could have a big impact on market growth is the lack of proper diagnosis of migraines.
Allergan, Endo International, GlaxoSmithKline, Impax, Pfizer, Abbott, Aegis Therapeutics, Aeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, AstraZeneca, Bayer, CoLucid, Dr. Reddy’s Laboratories, Eisai, Eli Lilly, Ethypharm, IntelGenx, Johnson & Johnson, Klaria, Kowa Pharmaceuticals America, Luitpold Pharmaceuticals, Meda, Merck, OptiNose, Pfizer, Pozen, Raptor, RedHill, SUDA, Teva, TG Therapeutics, NValeant, Winston Pharmaceuticals, Zogenix.